Trinity Biotech PLC has successfully concluded its annual general meeting (AGM), held on September 30, 2026, where shareholders approved all proposed resolutions with a remarkable majority. This outcome highlights strong support from shareholders and indicates a stable governance structure within the company.

The resolutions included the re-appointment of Grant Thornton as the statutory auditor, which will remain in place until the next AGM. Additionally, shareholders authorized the board of directors to determine the auditors' remuneration. Another key resolution involved the re-appointment of Dr. Andrew Omidvar as a director of the company.

This approval, with a minimum of 95% of votes cast in favor, demonstrates the confidence shareholders have in Trinity Biotech's management and strategic direction. Such strong backing can be crucial as the company continues to operate in the competitive field of in vitro and in vivo diagnostic substances.

Trinity Biotech operates under the SIC code 2835, which encompasses businesses engaged in the development and production of diagnostic substances. The results of this AGM may influence how similar companies in the industry approach shareholder engagement and governance practices.

Looking ahead, the next steps for Trinity Biotech are not detailed in the filing. However, the successful resolutions set a positive tone for the company's future operations and strategic initiatives.